OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 1044-1054
Closed Access | Times Cited: 80
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 1044-1054
Closed Access | Times Cited: 80
Showing 1-25 of 80 citing articles:
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 659-659
Open Access | Times Cited: 289
Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 659-659
Open Access | Times Cited: 289
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 789-799
Closed Access | Times Cited: 27
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 789-799
Closed Access | Times Cited: 27
UK guidelines for the management of soft tissue sarcomas
Andrew Hayes, Ioanna Nixon, D. Strauß, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 18
Andrew Hayes, Ioanna Nixon, D. Strauß, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 18
Therapeutic advances in leiomyosarcoma
Kristine Peregrino Lacuna, Sminu Bose, Matthew Ingham, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Kristine Peregrino Lacuna, Sminu Bose, Matthew Ingham, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma – a retrospective single-centre analysis
Anton Burkhard‐Meier, Vera Valerie Rechenauer, Luc M. Berclaz, et al.
Acta Oncologica (2025) Vol. 64, pp. 56-62
Open Access | Times Cited: 1
Anton Burkhard‐Meier, Vera Valerie Rechenauer, Luc M. Berclaz, et al.
Acta Oncologica (2025) Vol. 64, pp. 56-62
Open Access | Times Cited: 1
Chemotherapeutic drugs for soft tissue sarcomas: a review
Zhichao Tian, Weitao Yao
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
Zhichao Tian, Weitao Yao
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Erlinda M. Gordon, Sant P. Chawla, Walter Andree Tellez, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 906-906
Open Access | Times Cited: 17
Erlinda M. Gordon, Sant P. Chawla, Walter Andree Tellez, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 906-906
Open Access | Times Cited: 17
ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
Isabelle Ray‐Coquard, Paolo G. Casali, Sabrina Croce, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 10, pp. 1499-1521
Open Access | Times Cited: 7
Isabelle Ray‐Coquard, Paolo G. Casali, Sabrina Croce, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 10, pp. 1499-1521
Open Access | Times Cited: 7
Myxoid Liposarcomas: Systemic Treatment Options
Elise F. Nassif, Emily Z. Keung, Prapassorn Thirasastr, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 4, pp. 274-291
Closed Access | Times Cited: 15
Elise F. Nassif, Emily Z. Keung, Prapassorn Thirasastr, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 4, pp. 274-291
Closed Access | Times Cited: 15
First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Tao Li, Ying Dong, Yongzhong Wei, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4310-4317
Open Access | Times Cited: 5
Tao Li, Ying Dong, Yongzhong Wei, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4310-4317
Open Access | Times Cited: 5
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy
Qiwei Yang, Obianuju Sandra Madueke-Laveaux, Han Cun, et al.
Cells (2024) Vol. 13, Iss. 13, pp. 1106-1106
Open Access | Times Cited: 5
Qiwei Yang, Obianuju Sandra Madueke-Laveaux, Han Cun, et al.
Cells (2024) Vol. 13, Iss. 13, pp. 1106-1106
Open Access | Times Cited: 5
New strategies in soft tissue sarcoma treatment
Mariella Spalato Ceruso, Nathan El Ghazzi, Antoîne Italiano
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Mariella Spalato Ceruso, Nathan El Ghazzi, Antoîne Italiano
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review
Evelyne Roets, Winette van der Graaf, Bauke H.G. van Riet, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104345-104345
Open Access | Times Cited: 4
Evelyne Roets, Winette van der Graaf, Bauke H.G. van Riet, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104345-104345
Open Access | Times Cited: 4
Histology-Tailored Approach to Soft Tissue Sarcoma
Mai‐Kim Gervais, Georges Basile, Jean-Philippe Dulude, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 12, pp. 7915-7929
Closed Access | Times Cited: 4
Mai‐Kim Gervais, Georges Basile, Jean-Philippe Dulude, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 12, pp. 7915-7929
Closed Access | Times Cited: 4
Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review
Xuezhe Wang, Xinchi Luan, Wuliang Yin, et al.
Current Treatment Options in Oncology (2025) Vol. 26, Iss. 2, pp. 103-127
Closed Access
Xuezhe Wang, Xinchi Luan, Wuliang Yin, et al.
Current Treatment Options in Oncology (2025) Vol. 26, Iss. 2, pp. 103-127
Closed Access
SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024)
César Serrano, M.A. Arregui, Irene Carrasco, et al.
Clinical & Translational Oncology (2025)
Open Access
César Serrano, M.A. Arregui, Irene Carrasco, et al.
Clinical & Translational Oncology (2025)
Open Access
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas
Tarek Assi, Axel Le Cesne
Future Oncology (2025), pp. 1-4
Closed Access
Tarek Assi, Axel Le Cesne
Future Oncology (2025), pp. 1-4
Closed Access
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Gregory M. Coté, Sant P. Chawla, George D. Demetri, et al.
Future Oncology (2025), pp. 1-9
Open Access
Gregory M. Coté, Sant P. Chawla, George D. Demetri, et al.
Future Oncology (2025), pp. 1-9
Open Access
Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis
Luc M. Berclaz, Vindi Jurinović, Anton Burkhard‐Meier, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
Luc M. Berclaz, Vindi Jurinović, Anton Burkhard‐Meier, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access
Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center
Ted Kim, Clara Hao, Minggui Pan, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 79-79
Open Access
Ted Kim, Clara Hao, Minggui Pan, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 79-79
Open Access
Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses
Haoyi Zheng, Huichun Zhan
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Haoyi Zheng, Huichun Zhan
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Retrospective Analysis of BRCA -Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors
M.B. Rao, Madeline Merrill, Mary Troxel, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
M.B. Rao, Madeline Merrill, Mary Troxel, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib
Bo-Kyeong Kang, Sun-Jae Lee, Ki Ho Seol, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2921-2921
Open Access
Bo-Kyeong Kang, Sun-Jae Lee, Ki Ho Seol, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2921-2921
Open Access
The Decline and Fall of the Current Chemotherapy Paradigm in Soft Tissue Sarcoma
John Rieth, Varun Monga, Mohammed Milhem
Cancers (2025) Vol. 17, Iss. 7, pp. 1203-1203
Open Access
John Rieth, Varun Monga, Mohammed Milhem
Cancers (2025) Vol. 17, Iss. 7, pp. 1203-1203
Open Access
MiR-27b-3p ameliorates DOX-induced cardiotoxicity by suppressing myocardial inflammation and oxidative stress in mice and cardiomyocytes
Ying Gao, Shujun Yang
Drug and Chemical Toxicology (2025), pp. 1-16
Closed Access
Ying Gao, Shujun Yang
Drug and Chemical Toxicology (2025), pp. 1-16
Closed Access
